Interleukin-6 induces cellular insulin resistance in hepatocytes.

By Joseph J. Senn, P. Klover, I. Nowak, R. Mooney. Diabetes, 2002

932 citations recorded by the source corpus.

Subfields: Cancer Research, Epidemiology, Oncology

View Paper: https://www.semanticscholar.org/paper/36208c8db88a983cd95cb3bf04dfaba354c9a505

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cancer Research

In Epidemiology

In Oncology

Citations in the corpus

Systemic inflammation in nonalcoholic fatty liver disease is characterized by elevated levels of CCL2. (2006, result): “In fact, like TNFa, IL-6 may interfere with insulin signaling [22], thereby favoring steatosis and inflammation, although somewhat discrepant results have been reported [23,24].”
Tumor necrosis factor-alpha induces skeletal muscle insulin resistance in healthy human subjects via inhibition of Akt substrate 160 phosphorylation. (2005, background): “Elevations in IL-6 may lead to hepatic insulin resistance (40); however, effects on insulin signaling and glucose metabolism in skeletal muscle and adipose tissue are equivocal.”
Metabolic Syndrome and Insulin Resistance: Underlying Causes and Modification by Exercise Training (2013, positive): “laboratories indicates that IL-6 induces insulin resistance in cultured hepatocytes and hepatoma cells (584), impairs insulin action, and promotes lipolysis in adipocytes (376, 554, 646).”
Visceral Fat Adipokine Secretion Is Associated With Systemic Inflammation in Obese Humans (2007, background): “The direct secretion of IL-6 into the portal vein has important metabolic consequences because IL-6 stimulates hepatic acute-phase reactant production (18), impairs insulin-mediated glycogenesis (19), and stimulates hepatic gluconeogenesis (20).”
Senescence-messaging secretome: SMS-ing cellular stress (2009, background): “122 ), the latter inhibits phosphorylation of IRS1 in primary murine hepatocytes and hepatocellular carcinom”
Insulin resistance and chronic cardiovascular inflammatory syndrome. (2003, positive): “All of these findings are strengthened by the recent description of IL-6 receptors in human adipocytes (235) and by the dem- onstration that IL-6 impairs insulin signaling in primary mouse hepatocytes and human hepatocarcinoma cell line, HepG2 (236).”
Obesity, Oxidative Stress, Adipose Tissue Dysfunction, and the Associated Health Risks: Causes and Therapeutic Strategies (2015, background): “IL-6 causes hepatic insulin resistance by the inhibition of IRS phosphorylation mediated by activating the SOCS-3 protein.(271,330) Adipokines and renal dysfunction.”
Adipose tissue as an endocrine organ. (2010, background): “In adipocytes nd hepatocytes IL-6 has been demonstrated to inhibit the insulin ignaling pathway by up-regulating SOCS3 expression, which in urn is known to impair insulin-induced insulin receptor and IRS- phosphorylation (Senn et al., 2002, 2003; Rotter et al., 2003). owever, studies demonstrating t”